Company Overview

Evofem Biosciences, Inc. was a U.S.-based biopharmaceutical company focused on developing and commercializing innovative, non-hormonal women’s health products. The company operated primarily in the women’s sexual and reproductive health segment, with its core value proposition centered on addressing unmet needs in contraception and vaginal health through prescription therapeutics.

The company’s primary commercial product was Phexxi, a first-in-class, on-demand, non-hormonal vaginal contraceptive approved by the U.S. Food and Drug Administration. Evofem positioned itself uniquely by targeting patients seeking hormone-free alternatives and by leveraging a proprietary vaginal pH modulation technology. Founded in 2007, the company evolved from a development-stage biotechnology firm into a commercial-stage company following the FDA approval and launch of Phexxi, but later encountered financial distress that significantly altered its corporate trajectory.

Business Operations

Evofem’s business operations historically consisted of a single operating segment focused on the development, manufacturing, and commercialization of women’s health pharmaceutical products, with revenues primarily derived from U.S. prescription sales of Phexxi. Commercial activities included physician outreach, patient education, and managed-care engagement within the United States. The company did not report meaningful international commercial revenue prior to its restructuring.

The company relied on third-party manufacturers for product supply and external partners for certain commercialization and distribution functions. In 2023, Evofem Biosciences, Inc. filed for Chapter 11 bankruptcy protection and subsequently sold substantially all of its operating assets, including rights to Phexxi, to a newly formed entity. Following this transaction, the public company ceased active commercial operations. Data inconclusive based on available public sources regarding any continuing revenue-generating activities at the public-company level after the asset sale.

Strategic Position & Investments

Prior to its bankruptcy filing, Evofem’s strategy focused on expanding adoption of Phexxi, pursuing label expansion opportunities, and developing additional indications using its vaginal pH regulator platform. Growth initiatives included lifecycle management of its core technology and exploration of potential partnerships to extend market reach.

The most significant strategic event in the company’s history was the 2023 court-approved sale of substantially all assets to Evofem Biosciences Operating Company, LLC (name reported in public filings), which transferred the commercial product and related intellectual property out of the public entity. As a result, the former publicly traded company no longer controlled operating subsidiaries or an active product portfolio. Any ongoing investment or technology development activities at the public entity level are not clearly disclosed in subsequent filings; data inconclusive based on available public sources.

Geographic Footprint

Evofem Biosciences, Inc. was headquartered in the United States, with historical operations concentrated entirely in North America. Commercial activities, regulatory approvals, and revenue generation were primarily U.S.-based, reflecting the domestic focus of Phexxi’s approval and launch strategy.

The company did not establish a significant direct operational footprint outside the United States prior to its restructuring. While international market potential was occasionally referenced in corporate communications, there is no verified evidence of sustained commercial operations or material investment outside the U.S. before or after the asset sale.

Leadership & Governance

Evofem was founded and led for much of its operating history by executives with experience in biotechnology commercialization and women’s health. Governance followed a standard U.S. public-company model, with oversight by a board of directors and executive management team. Leadership emphasized patient choice, non-hormonal solutions, and innovation in underserved areas of women’s health.

Key executives prior to the 2023 bankruptcy and asset sale included:

• Saundra Pelletier – Chief Executive Officer
• Tiffany Durkin – Chief Financial Officer
• Katherine Clayton – Chief Legal Officer & Corporate Secretary
• Kelli Lively – Chief Commercial Officer

Subsequent leadership structure of the public company following the divestiture of operating assets is not clearly detailed in publicly available disclosures; data inconclusive based on available public sources.